- RecruitingPHASE3
BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
This study looks at a new medicine called BGB-43395 combined with letrozole for advanced breast cancer. It compares this new combination to standard treatments (other CDK4/6 inhibitors plus letrozole) for people who haven't had previous treatment for their advanced cancer.
For: HR+/HER2- Breast CancerUnited States · Australia · Brazil - Active not recruitingPHASE3
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
This study looks at a new combination treatment for advanced breast cancer that's hormone-positive and HER2-negative. It combines a new drug called capivasertib with existing treatments to see if it works better at slowing down the cancer's growth.
For: Locally Advanced (Inoperable) or Metastatic Breast CancerUnited States · Argentina · Australia - Active not recruitingPHASE3
A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer
This study looks at adding a drug called ribociclib to standard hormone therapy for people with early-stage breast cancer. It aims to see if this combination works better at preventing cancer from coming back and if it's safe for patients.
For: Early Breast CancerUnited States · Argentina · Australia - Active not recruitingPHASE3
Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)
This study is testing a new drug, AZD9833, for advanced breast cancer. It's for people whose cancer has a specific gene change (ESR1 mutation) and are already on certain treatments. Researchers want to see if adding AZD9833 works better than current medicines.
For: ER-Positive HER2-Negative Breast CancerUnited States · Australia · Austria - RecruitingPHASE1, PHASE2
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
This study looks at a new drug, ECI830, for advanced breast cancer and other solid tumors. Researchers want to see if it's safe and effective, both alone and with other common cancer medicines.
For: Advanced HR+/HER2- Breast Cancer · Advanced CCNE1-amplified Solid Tumors · Extensive-stage Small Cell Lung CancerUnited States · Australia · Canada - RecruitingPHASE3
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
This study is for people with advanced breast cancer that has a specific genetic change (PIK3CA). It's testing a new drug, Tersolisib, alongside other cancer medicines, to see if it's safe and helps treat the disease effectively.
For: Breast Neoplasms · Neoplasm MetastasisUnited States · Argentina · Australia - RecruitingPHASE3
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
This study looks at new drug combinations for advanced breast cancer. It compares saruparib and camizestrant with common existing treatments to see which works best for people with specific genetic changes (BRCA1, BRCA2, or PALB2m) in their cancer.
For: Advanced Breast CancerUnited States · Argentina · Australia - Active not recruitingPHASE3
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
This study is looking at a new drug, PF-07220060, combined with letrozole for advanced breast cancer. It compares this new treatment to existing approved therapies to see if it's safe and works well for people whose cancer needs hormones to grow.
For: Breast CancerUnited States · Argentina · Australia - RecruitingPHASE4
The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials
This study, called FLOTILLA, offers continued access to cancer medicines encorafenib and binimetinib for people who have already taken part in earlier clinical trials. It's for those still benefiting from the treatment.
For: Solid TumorsUnited States · Australia · Brazil - RecruitingPHASE2
A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer
This study is looking at new treatments for early-stage breast cancer. It focuses on a specific type of breast cancer (ER-positive, HER2-negative) that has a particular gene change (PIK3CA mutation). Researchers want to see how safe and effective the new medicine, Inavolisib, is when combined with other known treatments.
For: Breast CancerUnited States · Argentina · Brazil - RecruitingPHASE4
Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients
This study looks at how well a breast cancer drug called ribociclib works for women with a specific type of advanced breast cancer and why it might or might not work. It also checks for side effects and how patients feel.
For: Breast Cancer · Breast Neoplasms · Breast Neoplasm FemaleGermany - Active not recruitingPHASE2
Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib
This study looks at a new way to pick the best treatment for advanced breast cancer by checking special bits of cancer DNA in the blood. It compares two drugs, alpelisib and ribociclib, when given with fulvestrant, to see which works better for certain patients.
For: Breast Cancer Stage IVFrance - RecruitingPHASE3
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
This study is testing a new drug, giredestrant, against a standard treatment for advanced breast cancer. It's for people whose cancer has grown resistant to previous hormone therapy, to see if giredestrant, combined with other drugs, works better and is safe.
For: Estrogen Receptor-Positive, HER2-Negative Advanced Breast CancerUnited States · Argentina · Australia - Active not recruitingPHASE3
Detect V / CHEVENDO (Chemo vs. Endo)
This study compares different treatments for advanced breast cancer that has spread. It aims to see if a combination of targeted therapies and hormone therapy works better than targeted therapies and chemotherapy, while also keeping quality of life high.
For: Metastatic Breast CancerGermany - RecruitingPHASE2
A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
This study is looking at a new combination of medicines for advanced breast cancer that has stopped responding to hormone therapy. It aims to see if combining inavolisib with ribociclib and fulvestrant works better than the current treatment.
For: Breast CancerUnited States · Argentina · Brazil - RecruitingPHASE1
[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer
This study looks at a new combination treatment for advanced breast cancer. It combines a special radiation drug ([177Lu]Lu-NeoB) with two existing medicines (ribociclib and fulvestrant) to see if it's safe and effective, especially for patients whose cancer has come back or worsened after previous hormone treatments.
For: Breast CancerUnited States · China · France - RecruitingPHASE3
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
This study looks at a new drug, palazestrant, combined with standard treatment (ribociclib) for advanced breast cancer that is ER-positive and HER2-negative. It compares this new combination to the standard treatment alone to see if it works better and is safe for people who haven't had other treatments for their advanced cancer.
For: Breast Cancer · Locally Advanced Breast Cancer · Metastatic Breast CancerUnited States · Australia · Austria - RecruitingPHASE1, PHASE2
A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors
This study looks at a new drug, AZD8421, for advanced breast cancer (ER+ HER2- type) and a type of ovarian cancer. It checks how safe and effective it is, sometimes alone and sometimes with other cancer medicines.
For: ER+ HER2- Advanced Breast Cancer · High-grade Serous Ovarian Cancer (HGSOC)United States · Australia · South Korea - RecruitingPHASE1, PHASE2
European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
This study is for children and young people with cancer that hasn't responded to usual treatments. It tests new medicines that target specific changes in cancer cells, aiming to find the right dose and see if they help. The goal is to find better ways to treat childhood cancer.
For: Pediatric CancerDenmark · France · Italy - Active not recruitingPHASE1, PHASE2
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)
This study looks at a new medicine, vepdegestrant (also called ARV-471), with ribociclib for advanced breast cancer. It's for cancer that has spread, is hormone-sensitive, and isn't responding to past treatments. The goal is to see if it's safe and effective.
For: Breast CancerUnited States · Canada · Italy - Active not recruitingPHASE2
Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma
This study is looking for new ways to treat advanced melanoma, a type of skin cancer. It's testing combinations of new medicines (LXH254, LTT462) with existing ones (Trametinib, Ribociclib) in people whose melanoma has progressed after previous treatments. The goal is to see how well these new combinations work and if they are safe.
For: MelanomaUnited States · Argentina · Australia - Active not recruitingPHASE1, PHASE2
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer
This study is testing a new drug called elacestrant with other breast cancer medicines. It's for people with a specific type of advanced breast cancer that has spread. The main goals are to see if these drug combinations are safe and if they can help shrink the cancer.
For: Breast Cancer · Metastatic Breast CancerUnited States · Argentina · Australia - Active not recruitingPHASE1
Study of INCB123667 in Subjects With Advanced Solid Tumors
This study is testing a new drug, INCB123667, for people with advanced solid tumours. It will look at how safe the drug is, how it's used with other treatments, and if it could help shrink tumours. It's an early-stage study.
For: Solid TumorsUnited States · France · Italy - RecruitingPHASE2
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
This study is looking at new drug combinations to treat certain types of brain tumours in children and young adults. It aims to see if combining ribociclib with either everolimus or temozolomide can help patients live longer and improve their health.
For: High Grade Glioma · Diffuse Intrinsic Pontine Glioma · Anaplastic AstrocytomaUnited States · Australia · Canada